A Phase 2 interventional study of Randomized: 40 mg Paltusotine and Randomized: 80 mg Paltusotine in Carcinoid Syndrome, Carcinoid and Carcinoid Tumor, sponsored by Crinetics Pharmaceuticals Inc.. Completed at 35 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Crinetics Pharmaceuticals Inc. (part of Vertex Pharmaceuticals Incorporated) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Serotonin Syndrome with a site in United States — none open to participants now, 2 under way, 1 of them phase 3. Serotonin Syndrome · United States.
Among the 18 studies in Serotonin Syndrome with a site in United States, this one is the 8th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 2, and was the 17th registered.
35 studies on the registry are indexed under Serotonin Syndrome; 1 is open to participants now.
Browse Serotonin Syndrome studies →None of the 18 studies in Serotonin Syndrome with a site in United States is open now. The open studies under Serotonin Syndrome, anywhere →
This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 6
First in 2004; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is above the median of 20 across 23 interventional studies indexed under Serotonin Syndrome.
Median enrollment 30 across the 16 interventional studies, 112 across the 2 observational. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Crinetics Pharmaceuticals Inc., one of the names counted as Vertex Pharmaceuticals Incorporated. Under that name alone:
Crinetics Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Vertex Pharmaceuticals Incorporated has 2 studies filed under Serotonin Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Serotonin Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07087054Phase 3Crinetics Pharmaceuticals Inc.Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | 2027-08 |
| NCT04993261M.D. Anderson Cancer CenterAn Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Serotonin Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.
This is a Phase 2, randomized, open-label, parallel-group, multicenter study designed to evaluate the safety, pharmacokinetics, and efficacy of paltusotine treatment in subjects with carcinoid syndrome. The study was conducted in 2 parts: a Randomized Treatment Phase (RTP) which is completed, and an Open-label Extension (OLE) Phase which is still ongoing. The RTP consisted of paltusotine treatment for 8 weeks. Subjects who completed the RTP were eligible to enter the OLE Phase at the recommendation of the Investigator. In the ongoing OLE Phase, paltusotine is being administered for a further 102 weeks. The total duration of paltusotine treatment for the combined RTP and OLE Phase is up to 110 weeks (28 months).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Male or female subjects ≥18 years of age. 2. Documented carcinoid syndrome requiring medical therapy.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received paltusotine 40mg, in tablet form, orally, daily, for 8 weeks.
Drug: Randomized: 40 mg Paltusotine
Participants received paltusotine 80mg, in tablet form, orally, daily for 8 weeks.
Drug: Randomized: 80 mg Paltusotine
Two 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 80 mg)
Four 20 mg tablets QD (Potential post-randomization dose escalation based on efficacy and acceptable tolerability: up to 120 mg)
Safety - Incidence of Treatment-emergent Adverse Events (TEAEs)
Incidence of TEAEs, including serious TEAEs and TEAEs leading to discontinuation; change from baseline to the EOR in safety parameters: clinical laboratory tests, physical exam findings, vital signs, 12-lead ECG, and 24-hour continuous cardiac monitoring (only for subjects on 120 mg dose). In addition to all-cause mortality, deaths were categorized by primary cause (e.g., cardiovascular) based on medical adjudication. Events were coded using MedDRA and summarized by treatment group, system organ class, and preferred term. TEAEs were reported per randomized arm. There were 2 randomized arms (40 mg and 80 mg paltusotine, with up-or down-dose titration permitted for symptom control). Results are analyzed based on the initially assigned randomization arm, regardless of the actual dose received.
Time frame: First dose of investigational medicine to End of Randomized Treatment Phase (8 weeks)
Pharmacokinetics (PK) of Paltusotine
Steady state trough levels by dose and visit for Randomized Treatment Phase (RTP). The "Overall Number of Participants Analyzed" displayed at the top of the PK summary table represents the total number of participants who received each dose at any point during the trial, factoring in dose titrations. PK results are summarized by actual dose taken right before the time of sample collection, rather than by randomized dose. Participants may be included in different dose groups for different visits due to dose titration.
Time frame: Measured at each visit (pre and post dose) up to Week 8 (i.e., End of Randomized Treatment Phase [EOR])
In general, results are reported based on the dose assigned at randomization, regardless of the actual dose received.
| Milestone | 40 mg Paltusotine | 80 mg Paltusotine |
|---|---|---|
| Started | 18 | 18 |
| Adverse event | 1 | 1 |
| Physician decision | 0 | 3 |
| Withdrawal by subject | 0 | 1 |
| Completed | 17 | 13 |
| Not completed | 1 | 5 |
Incidence of TEAEs, including serious TEAEs and TEAEs leading to discontinuation; change from baseline to the EOR in safety parameters: clinical laboratory tests, physical exam findings, vital signs, 12-lead ECG, and 24-hour continuous cardiac monitoring (only for subjects on 120 mg dose). In addition to all-cause mortality, deaths were categorized by primary cause (e.g., cardiovascular) based on medical adjudication. Events were coded using MedDRA and summarized by treatment group, system organ class, and preferred term. TEAEs were reported per randomized arm. There were 2 randomized arms (40 mg and 80 mg paltusotine, with up-or down-dose titration permitted for symptom control). Results are analyzed based on the initially assigned randomization arm, regardless of the actual dose received.
| participants | 40 mg Paltusotine | 80 mg Paltusotine |
|---|---|---|
| Treatment-Emergent Adverse Events (TEAE) | 16 | 15 |
| TEAE Related to CS Symptoms | 10 | 9 |
| Highest Severity of TEAE: Severe TEAE | 3 | 1 |
| Highest Severity of TEAE: Moderate TEAE | 6 | 7 |
| Highest Severity of TEAE: Mild TEAE | 7 | 7 |
| Serious TEAE | 2 | 2 |
| Treatment Related TEAE | 10 | 13 |
| Treatment Related Serious TEAE | 0 | 0 |
| TEAE Leading to Study Discontinuation | 1 | 1 |
| TEAE Leading to Actions Taken with Study Treatment: Dose Increased | 3 | 1 |
| TEAE Leading to Actions Taken with Study Treatment: Dose Decreased | 0 | 2 |
| Actions Taken with Study Treatment: Drug Withdrawn | 0 | 1 |
| Actions Taken with Study Treatment: Drug Interrupted | 3 | 2 |
| Actions Taken with Study Treatment: Dose Not Changed | 16 | 15 |
| Actions Taken with Study Treatment: Not Applicable | 2 | 4 |
Steady state trough levels by dose and visit for Randomized Treatment Phase (RTP). The "Overall Number of Participants Analyzed" displayed at the top of the PK summary table represents the total number of participants who received each dose at any point during the trial, factoring in dose titrations. PK results are summarized by actual dose taken right before the time of sample collection, rather than by randomized dose. Participants may be included in different dose groups for different visits due to dose titration.
| ng/mL | 40 mg Paltusotine | 80 mg Paltusotine | 120 mg Paltusotine |
|---|---|---|---|
| WEEK 1 (POST-DOSE) | 188 ± 80.8 | 360 ± 103.3 | — |
| WEEK 2 (PRE-DOSE) | 61.4 ± 153.5 | 193 ± 83.5 | — |
| WEEK 2 (POST-DOSE) | 217 ± 90.5 | 473 ± 78.7 | 1240 ± 0.0 |
| WEEK 4 (PRE-DOSE) | 68.2 ± 179.1 | 158 ± 74.7 | 218 ± 0.0 |
| WEEK 4 (POST-DOSE) | 209 ± 202.1 | 462 ± 82.7 | 545 ± 184.5 |
| WEEK 6 (PRE-DOSE) | 57.8 ± 188.8 | 155 ± 63.1 | 146 ± 58.4 |
| WEEK 6 (POST-DOSE) | 261 ± 108.6 | 532 ± 89.4 | 474 ± 79.0 |
| WEEK 8 - EOR (PRE-DOSE) | 63.3 ± 122.1 | 165 ± 44.5 | 201 ± 69.1 |
Collected over Adverse event data were collected over the 8 weeks of the RTP phase, and an EOS Visit was to occur to collect the safety data and other assessments, 28 days after last dose of study drug and was required for subjects who completed the study or early terminated. TEAE data were summarized from first dose date until last dose date (end of RTP or early term) plus 28 days (Safety follow up).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 40 mg Paltusotine | 0/18 (0%) | 2/18 (11.1%) | 16/18 (88.9%) |
| 80 mg Paltusotine | 1/18 (5.6%) | 2/18 (11.1%) | 15/18 (83.3%) |
| Event | 40 mg Paltusotine | 80 mg Paltusotine |
|---|---|---|
| Cardiac failureCardiac disorders | 0/18 | 1/18 |
| DehydrationMetabolism and nutrition disorders | 0/18 | 1/18 |
| Large intestinal obstructionGastrointestinal disorders | 0/18 | 1/18 |
| EncephalopathyNervous system disorders | 1/18 | 0/18 |
| Infections and infestationsRenal and urinary disorders | 1/18 | 0/18 |
| Event | 40 mg Paltusotine | 80 mg Paltusotine |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/18 | 9/18 |
| Abdominal painGastrointestinal disorders | 3/18 | 6/18 |
| HeadacheNervous system disorders | 5/18 | 3/18 |
| NauseaGastrointestinal disorders | 2/18 | 5/18 |
| FlushingVascular disorders | 3/18 | 2/18 |
| Alanine aminotransferase increasedInvestigations | 0/18 | 3/18 |
| FatigueGeneral disorders | 2/18 | 2/18 |
| AstheniaGeneral disorders | 1/18 | 2/18 |
| Amylase increasedInvestigations | 2/18 | 1/18 |
| Aspartate aminotransferase increasedInvestigations | 0/18 | 2/18 |
| Age, Categorical(Participants) | 40 mg Paltusotine | 80 mg Paltusotine | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 9 | 20 |
| >=65 years | 7 | 9 | 16 |
| Age, Continuous(years) | 40 mg Paltusotine | 80 mg Paltusotine | Total |
|---|---|---|---|
| Mean | 58.6 (35 to 83) | 62.9 (41 to 78) | 60.8 (35 to 83) |
| Sex: Female, Male(Participants) | 40 mg Paltusotine | 80 mg Paltusotine | Total |
|---|---|---|---|
| Female | 8 | 11 | 19 |
| Male | 10 | 7 | 17 |
| Ethnicity (NIH/OMB)(Participants) | 40 mg Paltusotine | 80 mg Paltusotine | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 8 | 15 |
| Not Hispanic or Latino | 10 | 9 | 19 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | 40 mg Paltusotine | 80 mg Paltusotine | Total |
|---|---|---|---|
| Europe | 1 | 1 | 2 |
| United States | 9 | 10 | 19 |
| South America | 8 | 7 | 15 |
| Body Mass Index (BMI)(kg/m^2) | 40 mg Paltusotine | 80 mg Paltusotine | Total |
|---|---|---|---|
| Mean | 29.057 ± 4.3181 | 28.609 ± 10.8261 | 28.833 ± 17.58 |
| Symptomatic Entry Criteria Met - n (%)(Participants) | 40 mg Paltusotine | 80 mg Paltusotine | Total |
|---|---|---|---|
| Bowel Movement Criteria Only | 6 | 8 | 14 |
| Flushing Criteria Only | 4 | 7 | 11 |
| Bowel Movement and Flushing Criteria | 8 | 3 | 11 |
| Baseline Mean Daily Bowel Movements (/day)(BMs per day) | 40 mg Paltusotine | 80 mg Paltusotine | Total |
|---|---|---|---|
| Mean | 3.881 ± 2.0398 | 3.343 ± 1.3705 | 3.612 ± 1.7343 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2022 to primary completion in Mar 2024, 22 months.
Results were first posted in Oct 2025, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Paltusotine
Crinetics Pharmaceuticals Inc. →